Oragenics

Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock.

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET.

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company's progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions.

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury.

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of common stock at an offering price of $0.55 per share and $0.549 per pre-funded warrant. Immediately after the closing of the offering, the Company has 8,659,071 shares of common stock outstanding and pre-funded warrants to acquire up to 5,028,206 shares of common stock outstanding. The exercise price of each pre-funded warrant is $0.001.

Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.55 per share (or $0.549 per pre-funded warrant in lieu thereof).

Oragenics, Inc. Announces Pricing of Public Offering

• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for concussion; drug, ONP-002, could be first of its kind to treat concussion SARASOTA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and key 2024 business progress. The Company continues to execute its business strategy to develop and advance its lead candidate, ONP-002, for the treatment of concussion. Phase 2 human trials are being planned with anticipation of starting in the fourth quarter of this year.

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced its lead candidate for treating concussion, ONP-002, successfully completed a study that indicates it does not cause DNA damage and genotoxicity in an animal model.

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Oragenics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Oragenics, Inc. Announces Proposed Public Offering

Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the con.

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve.

Oragenics, Inc. Files 10K and Provides Company Update

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics' lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA clinical trial. The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion. Oragen.

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts, and offering expenses.

Oragenics Announces Closing of Public Offering

Oragenics (NYSEMKT: OGEN ) stock is falling on Wednesday after the antibiotics development company announced details of a public offering for its shares. Oragenics is selling 1.4 million shares of OGEN stock for $1.50 each.

Why Is Oragenics (OGEN) Stock Down 45% Today?

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company.

Oragenics Announces Pricing of Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants to purchase shares of common stock (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering. The Company expects to grant the underwriters a 45-day.

Oragenics Announces Proposed Public Offering

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company's Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the “Separation Agreement”), pursuant to which Ms. Murphy's employment with the Company terminated effective Febru.

Oragenics, Inc. Announces Leadership Transition

SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its engagement agreement with its investment bank has expired and that it does not intend to extend the engagement at this time due to market conditions. About ONP-002 ONP-002 is a fully synthetic neurosteroid being developed to treat mTBI. In preclinical studies, the drug demonst.

News for Oragenics Stock (OGEN)